Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Buy
56
IDXX Quote, Financials, Valuation and Earnings
Last price:
$413.58
Seasonality move
:
5.97%
Day range:
$409.84 - $414.25
52-week range:
$398.50 - $583.39
Dividend yield:
0%
P/E ratio:
39.89x
P/S ratio:
8.99x
P/B ratio:
20.93x
Volume:
159.9K
Avg. volume:
623.5K
1-year change:
-25.34%
Market cap:
$33.9B
Revenue:
$3.7B
EPS (TTM):
$10.37
Analysts' Opinion
-
Consensus RatingIDEXX Laboratories has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $478.62, IDEXX Laboratories has an estimated upside of 15.72% from its current price of $413.62.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $400.00 representing 100% downside risk from its current price of $413.62.
Fair Value
-
According to the consensus of 9 analysts, IDEXX Laboratories has 15.72% upside to fair value with a price target of $478.62 per share.
IDXX vs. S&P 500
-
Over the past 5 trading days, IDEXX Laboratories has underperformed the S&P 500 by -5.93% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
IDEXX Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IDEXX Laboratories has grown year-over-year revenues for 39 quarters straight. In the most recent quarter IDEXX Laboratories reported revenues of $975.5M.
Earnings Growth
-
IDEXX Laboratories has grown year-over-year earnings for 1 quarter straight. In the most recent quarter IDEXX Laboratories reported earnings per share of $2.80.
Enterprise value:
34.4B
EV / Invested capital:
13.82x
Price / LTM sales:
8.99x
EV / EBIT:
30.58x
EV / Revenue:
8.96x
PEG ratio (5yr expected):
6.86x
EV / Free cash flow:
43.44x
Price / Operating cash flow:
43.62x
Enterprise value / EBITDA:
27.50x
Gross Profit (TTM):
$2.3B
Return On Assets:
26.31%
Net Income Margin (TTM):
22.53%
Return On Equity:
57.37%
Return On Invested Capital:
35.27%
Operating Margin:
31.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $3.3B | $3.6B | $3.8B | $915.5M | $975.5M | |
| Gross Profit | $2B | $2.1B | $2.3B | $548M | $596M | |
| Operating Income | $871.4M | $1.1B | $1.1B | $275.3M | $303.9M | |
| EBITDA | $983.3M | $1.2B | $1.3B | $305.5M | $340.7M | |
| Diluted EPS | $7.87 | $9.80 | $10.37 | $2.53 | $2.80 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $868.7M | $938M | $1.1B | $1.4B | $1.4B | |
| Total Assets | $2B | $2.4B | $2.6B | $3.1B | $3.4B | |
| Current Liabilities | $526.8M | $633.8M | $1.2B | $970.2M | $1B | |
| Total Liabilities | $1.6B | $1.6B | $2.2B | $1.8B | $1.7B | |
| Total Equity | $441.1M | $755.5M | $476M | $1.3B | $1.6B | |
| Total Debt | $903.3M | $853M | $1.4B | $1B | $873.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $579.5M | $830.1M | $916.8M | $272.4M | $220.1M | |
| Cash From Investing | -$190.2M | -$144M | -$197.7M | -$27.8M | -$27.4M | |
| Cash From Financing | -$420M | -$456.9M | -$747.1M | -$43M | -$291M | |
| Free Cash Flow | $438.1M | $679.8M | $792.6M | $238.3M | $192M | |
IDXX
Sector
Market Cap
$33.9B
$46.1M
Price % of 52-Week High
70.9%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
1.59%
-0.6%
1-Year Price Total Return
-25.35%
-30.52%
Beta (5-Year)
1.368
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$418.58
200-day SMA
Sell
Level
$480.85
Bollinger Bands (100)
Sell
Level
428.46 - 492.06
Chaikin Money Flow
Buy
Level
131.9M
20-day SMA
Sell
Level
$426.98
Relative Strength Index (RSI14)
Sell
Level
39.51
ADX Line
Sell
Level
12.73
Williams %R
Buy
Level
-81.0634
50-day SMA
Sell
Level
$432.80
MACD (12, 26)
Sell
Level
-5.51
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
141.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (19.9234)
Buy
CA Score
(Annual)
Level (0.9734)
Buy
Beneish M-Score
(Annual)
Level (-2.3716)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.7106)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Stock Forecast FAQ
In the current month, IDXX has received 3 Buy ratings 6 Hold ratings, and 0 Sell ratings. The IDXX average analyst price target in the past 3 months is $478.62.
-
Where Will IDEXX Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that IDEXX Laboratories share price will rise to $478.62 per share over the next 12 months.
-
What Do Analysts Say About IDEXX Laboratories?
Analysts are divided on their view about IDEXX Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IDEXX Laboratories is a Sell and believe this share price will drop from its current level to $400.00.
-
What Is IDEXX Laboratories's Price Target?
The price target for IDEXX Laboratories over the next 1-year time period is forecast to be $478.62 according to 9 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is IDXX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IDEXX Laboratories is a Hold. 6 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of IDXX?
You can purchase shares of IDEXX Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IDEXX Laboratories shares.
-
What Is The IDEXX Laboratories Share Price Today?
IDEXX Laboratories was last trading at $413.58 per share. This represents the most recent stock quote for IDEXX Laboratories. Yesterday, IDEXX Laboratories closed at $413.62 per share.
-
How To Buy IDEXX Laboratories Stock Online?
In order to purchase IDEXX Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
